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Objective. Suture–hole bleeding is a considerable problem in vascular procedures using polytetrafluoroethylene (PTFE)
grafts. This study aimed to study the efficacy of TachoCombw H patches in controlling suture–hole bleeding.
Design. Prospective randomised controlled trial.
Materials and methods. Patients undergoing femoral anastomosis and femoral or carotid patch angioplasty with PTFE
grafts were prospectively randomised to TachoCombw H patches or standard compression with surgical swabs.
Results. Twenty four patients were randomised (12 patients in each treatment group). The median time to haemostasis was
300 (range 180–600) s in patients treated with TachoCombw H and 660 (range 180–1200) s in the control group. The log
rank test of equality over treatments based on the 22 patients with assessment of time to haemostasis showed statistical
significance (p ¼ 0.0134). There were no serious complications associated with use of TachoCombw H patches.
Conclusion. TachoCombw H patches were found to be safe and effective for the control of suture–hole bleeding in patients
undergoing vascular reconstruction with PTFE grafts.
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Introduction
Suture hole bleeding is a considerable problem in
vascular reconstructive procedures using polytetra-
fluroethylene (PTFE) grafts.1 Traditionally this is
managed by compression with surgical swabs and
reversal of heparin. Other methods such as application
of oxidised cellulose, gelatine sponge, different forms
of collagen and glues have also been tried with
variable success.
The TachoCombw H patch consists of an equine
collagen sponge coated with the haemostatic factors
fibrinogen and thrombin. It is a ready-to-use and
absorbable haemostatic dressing.
The aim of the study was to compare the efficacy
and safety of TachoCombw H patches against standard
surgical compression to control the suture hole
bleeding from PTFE grafts.
Materials and Methods
A total sample size of 60 patients (30 in each treatment
group) was originally planned after a power calcu-
lation but as the effectiveness of TachoCombw H was
also demonstrated in a similar study, conducted
simultaneously, the present study was stopped pre-
maturely and only 24 patients were randomised. Three
centres participated in the study contributing 17, 5 and
3 patients, respectively. One patient was excluded
prior to randomisation and two more had to be
withdrawn because of deviation from study protocol
and insufficient data collection, giving a total of 22
patients. Femoral anastomoses and femoral or carotid
patch angioplasties were evaluated. The anastomoses
and patches were performed using 5–0 or 6–0 prolene
sutures.
The study was approved by the local ethics
committee, and informed consent was obtained before
inclusion. Patients were excluded if the patch length
exceeded 8 cm, if fibrin glues or any local haemostyp-
tics were used during the operation or if the patient
was allergic to any of the components of TachoCombw
H. Patients who did not require additional haemo-
static measures on releasing the clamps were also
excluded from the study. Patients were randomised by
the sealed code envelope method to either treatment
with TachoCombw H patches or to standard com-
pression with surgical swabs. The randomization code
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envelopes were opened just before the application of
haemostatic measures. The nature of the treatments
precluded blinding of the study. Therefore, an inde-
pendent nurse recorded all the variables assessed.
Patients in the TachoCombw H arm of the study
were treated by applying TachoCombw H patches,
after moistening with physiological saline. Dosage (the
number of patches) used depended on the size of the
wound area to be covered. One patch of TachoCombw
H is 9.5 £ 4.8 £ 0.5 cm3 in size. It contains collagen
from equine tendons, human fibrinogen, human
thrombin, bovine aprotinin and riboflavin (to mark
the active side). TachoCombw H is produced by
Nycomed (Linz, Austria), and it is a further develop-
ment of the original TachoCombw, where bovine
thrombin has been replaced by human thrombin due
to concerns of antibody formation against bovine
thrombin2 and transmission of bovine spongiform
encephalitis (BSE).3 The moistened patch of Tacho-
CombwH was applied with the yellow active side onto
the wound surface after blood and other fluids were
cleansed from the wound area. The patch had to
extend at least 1 cm beyond the wound edge and
pressure was applied for 3 min. Haemostasis was
assessed at the end of this period. If haemostasis was
not achieved by this time, pressure was reapplied for
another 2 min. If haemostasis was still insufficient, the
first patch was replaced with a new one and
compression applied for a maximum of 5 min before
considering other methods. If a patch became dis-
placed by bleeding during the first 5 min, it was
replaced with a new piece. Patients in the control arm
received compression with 10 £ 10 cm2 surgical
swabs. If haemostasis was suboptimal at the end of
10 min then other methods were adopted as necessary.
The main variable measured was the time to
haemostasis. Haemostasis was defined as the time
when the wound was completely dry or sufficiently
dry to complete the operation without additional
haemostasis. Survivor functions of time to haemostasis
for the two treatment groups were tested by a log rank
test using SASw software. Life time estimates were
made based on recordings in one minute intervals
from time 3 to 10 min. Recordings of time to
haemostasis beyond 10 min were censored. Due to
the small number of patients no other statistical
analyses were performed. Blood loss during the
operation, duration of operation, drain volume,
requirement for blood transfusion, surgeons rating of
efficacy (very good, good, satisfactory or unsatisfac-
tory), and coagulation parameters were also recorded.
Blood loss after release of cross-clamping was
measured by weighing the swabs used in the relevant
wound, from the time TachoCombw H or compresses
were applied until achieving haemostasis. Graft type
and size were recorded. Duration of the operation was
measured from the time of incision to the completion
of skin suture.
Results
Twenty four patients were randomised to give 12
patients in each treatment group of the study One
patient was withdrawn immediately after randomis-
ation (surgical compression group), and one patient
had no assessment of time to haemostasis (Tacho-
Combw H group). The mean age of patients was 70.6
(range 55–86) years in the TachoCombw H group and
66.3 (range51–71) years in the surgical control group.
There were no significant differences in any patient or
procedural characteristics including the use of anti-
platelet agents.
In the TachoCombw H group half a patch was used
in two patients, one patch in five patients and two
patches in five patients. Postoperative clotting par-
ameters were not altered by application of the patches.
There were no instances of intravascular thrombosis or
embolism subsequent to the application of Tacho-
Combw H.
The median time to haemostasis was 300 (range
180–600) s in TachoCombw H group and 660 (range
180–1200) s in the surgical compression group (Fig. 1).
The log rank test of equality over treatments based on
the 22 patients with assessment of time to haemostasis
showed statistical significance ðp ¼ 0:0134Þ:The survivor
Fig. 1. Box-and-whisker plot showing time to haemostasis,
mean (dot), median (line), 25–75 percentile (box), and range
(‘error bars’).
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functions of time to haemostasis are illustrated using
life table estimates based on the 22 patients with
assessment of time to haemostasis (Fig. 2).
Complete haemostasis was achieved within 3 min
in 3/12 patients (25%) in the TachoCombw H group
and 2/11 patients (18%) in the surgical compression
group. In the TachoCombw H group another 3/12
patients (25%) achieved haemostasis after application
for another 2 min making a total of 50% haemostasis
within 5 min. In the surgical compression group 2/11
more patients (18%) achieved complete haemostasis
after additional 7 min, making a total of 36% in 10 min.
No statistical analyses were performed for the
secondary endpoints. However, the mean blood loss
after cross-clamping as well as the mean drain volume
appeared to be substantially reduced in the Tacho-
Combw H group despite no difference in the mean
duration of surgery (Table 1).
A total of 16 adverse events occurred in nine
patients in the TachoCombw H group and 12 events
were recorded for 8 patients in the standard com-
pression group. The most frequent adverse events
were peripheral oedema, fever, post-operative haem-
orrhage, and post-operative wound infection. The
adverse events were equally distributed between the
two treatment groups except fever, which developed
in 4 TachoCombwH patients and in only one patient in
the standard compression group. Adverse events
classified as serious developed in two patients in the
TachoCombw H group and in two patients in the
standard compression group. One TachoCombw H
treated patient died of acute renal failure. None of the
serious adverse events were considered related to test
treatment, and only one non-serious adverse event
(pyrexia) was considered to be possibly related to the
test treatment.
Discussion
Collagen patches may be effective for delivering drugs
locally. In this study collagen was used to provide
fibrinogen and thrombin locally at the site of bleeding.
Upon contact with fluid the clotting factors of
TachoCombw H dissolve and form a fibrin network,
which glues the collagen sponge to the wound surface.
Combining the clotting factors in a collagen patch
provides a high concentration of clotting factors at the
site where it is specifically needed. The haemostatic
effectiveness of using TachoCombw H has previously
been proved in clinical studies.4,5 Liquid fibrin glue
preparations are likewise found to be effective in
achieving haemostasis.6 – 8 However, combining fibrin
glue components in a collagen patch facilitates ease of
application.
Despite the small number of patients enrolled, the
present study showed that TachoCombw H signifi-
cantly reduces the time to haemostasis. Haemostasis
was achieved within 5 min in 50% of the patients in the
TachoComb H group compared to only 36% within
10 min in the control group. In addition both intra- and
postoperative bleeding appeared to be substantially
reduced in the TachoCombwH arm.
TachoCombw H was well tolerated and none of the
serious adverse events observed in TachoCombw H
treated patients were considered related to test
treatment. The higher incidence of fever in Tacho-
CombwH treated patients may be coincidental as fever
Fig. 2. Life table estimates for time to haemostasis, i.e.
fraction of patients still bleeding at a given time. Continuous
line, TachoCombw H; broken line, compression group.
Table 1. Variables measured. Number of patients, n; one standard deviation, SD
Variable TachoComb H ðn ¼ 11Þ Control ðn ¼ 11Þ
Time to haemostasis (Mean ^ SD, s)
All procedures 376 ^ SD 176 606 ^ SD 315
Anastomosis 367 ^ SD186 ðn ¼ 9Þ 546 ^ SD 258 ðn ¼ 10Þ
Patch angioplasty 420 ^ SD 170 ðn ¼ 2Þ 1200 ðn ¼ 1Þ
Mean blood loss after cross-clamp removal (g) 38 93
Number of patients requiring blood transfusion 0 (0%) 2 (18%)
Duration of surgery (Mean values and range, min) 81 (51–110) 83 (50–144)
Drainage volume within 24 h (Mean value and range, ml) 61 (25–150) 160 (50–450)
Surgeons overall efficacy rating (Number of cases rated as
unsatisfactory)
2 (18%) 7 (64%)
Randomised Trial of TachoCombw H 551
Eur J Vasc Endovasc Surg Vol 27, May 2004
has not occurred more frequently than in control
patients, according to Nycomed safety reports.
In conclusion, TachoCombw H was found to be safe
and effective for control of suture hole bleeding in
patients undergoing vascular reconstruction with
PTFE grafts.
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